Members of the Sarah Cannon Blood Cancer Network are currently at the 2019 TCT I Transplantation and Cellular Therapy Meetings (formerly the BMT Tandem Meetings) to present insights on the latest developments in hematopoietic stem cell transplantation (HCT). This event is the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR), which brings together blood cancer experts from around the world to discuss the latest developments in HCT. Click here to view Sarah Cannon’s full presentation calendar.
Sarah Cannon is one of the world’s largest providers of blood and marrow transplant (BMT), conducting more than 1,100 transplants per year. The experience of our centers is reflected in the 14,000 transplants performed since inception.
Sarah Cannon Blood Cancer Network is formed by individual programs that have long been recognized as leaders in patient care and outcomes. By joining Sarah Cannon, these programs made a commitment to the highest level of quality standards, infrastructure, training and research to provide an unparalleled experience for patients seeking blood cancer treatment. The clinical and operational efficiencies inherent in standardization and coordination of capabilities make the Sarah Cannon Blood Cancer Network well-positioned to demonstrate superior value. Each of the blood and marrow transplant programs in the Sarah Cannon Blood Cancer Network are required to achieve FACT/JACIE accreditation, which certifies compliance with the comprehensive international standards for quality in cellular therapies.
Our integration of research, quality, training and technology ensures patient access to the highest standards of care.